DC-CIK联合氟尿嘧啶+顺铂化疗对局部进展期宫颈癌术后患者的疗效及安全性

目的:探讨DC-CIK联合氟尿嘧啶+顺铂化疗对局部进展期宫颈癌术后患者的影响。方法:2012年1月至2015年1月，前瞻性收集我院收治的局部进展期宫颈癌患者96例，均行宫颈癌根治术，术后将患者随机分为观察组和对照组，每组各48例。两组患者均给予氟尿嘧啶+顺铂化疗，观察组在此基础上给予DC-CIK辅助治疗，观察两组患者临床疗效。结果:观察组患者术后2年时复发率显著低于对照组(P=0.019)。两组患者术后死亡率差异无统计学意义(P>0.05)。与对照组比较，观察组治疗后CD4+T细胞显著增高(P=0.000)；CD4+/CD8+显著增高(P=0.000)；CD3+CD56+NKT细胞显著增高(P=0.000)。两组患者术后并发症无统计学差异(P>0.05)。结论:DC-CIK联合氟尿嘧啶+顺铂化疗可降低局部进展期宫颈术后患者复发率，改善临床预后，安全有效。

Efficacy and safety of DC-CIK combined with fluorouracil+cisplatin chemotherapy in patients with locally advanced cervical cancer after surgery

Objective:To investigate the effect of DC-CIK combined with fluorouracil+cisplatin chemotherapy on postoperative patients with locally advanced cervical cancer.Methods:From January 2012 to January 2015，96 patients with locally advanced cervical cancer were prospectively collected in our hospital.All patients received radical resection of cervical cancer，and then they were randomly assigned into an observation group or a control group with 48 cases in each group.Patients in the both groups received fluorouracil+cisplatin chemotherapy，and on the basis of this，patients in the observation group received DC-CIK for further treatment.The clinical efficacy of the both groups were studied.Results:When compared with the control group，patients in the observation group got a lower recurrence rate at 2 years since the operation (P=0.019).There was no significant differences between the two groups in postoperative mortality (P>0.05).Compared with the control group，the observation group after treatment of CD4+T cells was significantly increased (P=0.000).CD4+/CD8+ increased significantly (P=0.000).CD3+ CD56+NKT cells increased significantly (P=0.000).There was no significant difference in postoperative complications between the two groups (P>0.05).Conclusion:DC-CIK combined with fluorouracil+cisplatin chemotherapy can reduce the recurrence rate of locally advanced cervical surgery and improve the clinical prognosis，which is safe and effective.